Pfizer Inc. brought in more than $14-billion in sales during the recently completed first quarter from its COVID-19 vaccine Comirnaty and its new pill treatment for the virus, Paxlovid.
That includes Eliquis for preventing blood clots and strokes and the Prevnar 13 vaccine for preventing pneumonia and related bacterial diseases.The deal announced Tuesday is a step in that direction. Pfizer currently has no migraine treatments. U.S. regulators approved Nurtec ODT – which stands for orally disintegrating tablet – for treating migraines in February 2020 and for preventing them about a year ago.It brought in nearly $124-million in sales in the first quarter.
Last November, Pfizer said it would invest $350-million in Biohaven to help sell Nurtec ODT and the spray, zavegepant, outside the United States. Pfizer executives told analysts they expect annual revenue from Nurtec ODT and the spray to eventually peak above $6-billion.